60 Degrees Pharmaceuticals Inc. is facing potential delisting from the Nasdaq Capital Market after receiving notice from the Nasdaq Listing Qualifications Department. The company’s common stock failed to maintain a minimum bid price of 1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Because the company conducted a 1-for-5 reverse stock split within the past year, it is not eligible for the standard 180-day compliance period and is subject to immediate delisting under Nasdaq Listing Rule 5810(c)(A)$(iv). Additionally, the company’s warrants are also subject to delisting, as their continued listing requires the underlying security to remain listed on Nasdaq. 60 Degrees Pharmaceuticals has appealed the decision, which temporarily stays the suspension of trading pending the outcome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-007330), on January 23, 2026, and is solely responsible for the information contained therein.